Insulin Delivery Devices Market: Current Analysis and Forecast (2021-2027)
Insulin Delivery Devices Market is expected to grow at a CAGR of around 10% over the forecast period (2021-2027). The rise of this market is fueled by a growing diabetic population, obesity, and a sedentary lifestyle. Furthermore, advancements in human insulin delivery systems, innovations in insulin delivery system techniques, and healthy reimbursement policies, as well as rising awareness among the population about diabetes control and accessibility to insulin delivery systems, are all factors ensuring the market's growth.
Several government organizations are focusing on boosting the existing infrastructure for overall healthcare system development. Among the countries worldwide, the United States had the highest percentage of gross domestic product spent on health care in 2019. The U.S. spent nearly 17% of its GDP on health care services. Germany, Switzerland, and France followed the U.S. with distinctly smaller percentages. The United States had both significantly higher private and public spending on health compared with other developed countries.
The number of people with diabetes is increasing due to population growth, aging, urbanization, and increasing prevalence of obesity and physical inactivity. The prevalence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is projected to rise from 171 million in 2000 to 366 million in 2030.
Some of the major players operating in the market include Medtronic, Becton, Dickinson and Company, Novo Nordisk, Eli Lilly and Company, Sanofi, Insulet Corporation, Ypsomed Holding AG, Tandem Diabetes Care, Inc., Animas Corporation, Biocon Ltd, etc. Several M&A’s along with partnerships have been undertaken by these players to boost their presence in different regions.
Insights Presented in the Report
“Amongst Type, Insulin Pens segment dominated the market in 2020”
Based on Type, the market is segmented into Insulin Pens (Reusable, Disposable), Insulin Pumps (External, Tethered, Patch), Insulin Syringes, Insulin Jet Injectors and Other Devices. The Insulin Pens segment leads the Insulin Delivery Devices Market. Insulin pens are growing in popularity, and many people with diabetes nowadays use a pen to administer insulin as it allows more simple, accurate, and convenient delivery than using a vial and syringe.
“Amongst End-User, Patients/Homecare segment dominated the market in 2020.”
Based on End-User, the Insulin Delivery Devices market is segmented into Patients/Homecare and Hospitals & Clinics. The patients/homecare segment commanded the largest share of the insulin delivery devices market and is expected to grow at the highest CAGR during the forecast period. The growth of this segment can be attributed to the increasing diabetic population and rising healthcare expenditure.
“North America represents as the largest market.”
For a better understanding of the market adoption of Insulin Delivery Devices, the market is analyzed for the countries such as North America (US, Canada, Rest of North America), Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, Rest of Asia- Pacific), & Rest of World. Asia-Pacific dominated the market in 2020. North America dominated the market. The rising prevalence of diabetes and favorable reimbursement scenario in the United States and Canada, growing venture capital investments and IPOs in the United States, and FDA approvals to increase the commercial availability of insulin delivery devices in the United States all contribute to this region's large share.
Reasons to buy this report:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook